Drugs / ECC4703
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05552274 | Aug 2022 → Oct 2023 | metabolic dysfunction-associated steatohepatitis | Eccogene | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07726368 | Aug → Dec 2026 expected | NAFLD1, hyperlipidemia | Eccogene | Recruiting | No outcome recorded |
| Phase 1 | NCT07334080 | Jan 2026 → Apr 2027 expected | metabolic dysfunction-associated steatohepatitis | Eccogene | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07505303 | Mar → Oct 2026 expected | obesity disorder | Eccogene | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07288138 | Dec 2025 → Sep 2027 expected | metabolic dysfunction-associated steatohepatitis | Eccogene | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-10-06 | Eccogene | Regulatory Eccogene Receives U.S. FDA Clearance to Initiate Phase 2a MOSAIC Trial of ECC4703 and ECC0509 for MASH eccogene.com ↗
We are pleased to receive the FDA clearance to initiate our Phase 2a MOSAIC trial with ECC4703 and ECC0509 for MASH, which impacts millions of patients worldwide, said Jingye Zhou, Chief Executive Officer of Eccogene. |
| 2025-06-17 | Eccogene | Results Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide eccogene.com ↗
The combination therapy of ECC4703 and semaglutide or tirzepatide resulted in significantly greater weight loss compared to semaglutide or tirzepatide alone. |
| 2024-11-15 | Eccogene | Results Eccogene Announces Positive Phase 1 Data for Oral THR-β Full Agonist and Oral SSAO Inhibitor in Late-Breaking Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® eccogene.com ↗
Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signals |
| 2022-08-01 | Eccogene | Regulatory Eccogene Announces US IND Approval for THRβ agonist ECC4703 eccogene.com ↗
Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECC4703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07505303 ↗ |
| Action | Activate | “a THRβ Agonist (ECC4703)” NCT07288138 ↗ |
| Route | Oral | “ECC4703 will be administered as oral capsules during each dosing day.” NCT05552274 ↗ |